Regeneron Buy Rating: Navigating Challenges with a Promising Pipeline and Strategic Investments

Analyst John Newman of Canaccord Genuity maintained a Buy rating on Regeneron (REGN – Research Report), retaining the price target of $850.00.

John Newman’s rating is based on several factors, including the potential for Regeneron’s strong pipeline to offset current challenges. Despite the decline in EYLEA sales due to competition and pricing issues, the company’s investment in US manufacturing and its pipeline of new products, such as the Factor XI program, are seen as promising for long-term growth.
Additionally, while the EYLEA HD pre-filled syringe faces regulatory hurdles, the issue is considered addressable, and its resolution could positively impact future sales. The analyst also notes that the company’s strategic moves, like the Fujifilm deal, aim to enhance manufacturing capabilities, which could mitigate some of the negative impacts of potential tariffs. Overall, the Buy rating reflects confidence in Regeneron’s ability to navigate current headwinds and capitalize on future opportunities.

Newman covers the Healthcare sector, focusing on stocks such as Regeneron, Candel Therapeutics, and Adicet Bio. According to TipRanks, Newman has an average return of -6.8% and a 31.20% success rate on recommended stocks.

In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $800.00 price target.